{"filings":[{"id":2301399,"accession_number":"0001193125-26-354154","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2026-08-17T20:30:12+00:00","items":["4.01","5.02","7.01","9.01"],"status":"ready","headline":"ResMed dismisses KPMG, appoints PwC; Carol Burt to become Lead Director","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["KPMG dismissed as auditor Aug 13, 2026; PwC appointed for FY2027 subject to client acceptance.","No disagreements or reportable events with KPMG; KPMG letter filed as Exhibit 16.1.","Ron Taylor to retire after 21 years; not standing for reelection at Nov 18, 2026 annual meeting.","Carol Burt to become Lead Director effective Nov 15, 2026; on board since 2013, chairs Nominating and Governance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2105804,"accession_number":"0001193125-26-337962","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2026-08-06T20:05:37+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"ResMed Q4 revenue up 9% to $1.5B; non-GAAP EPS $2.95 (+16%); dividend raised 10%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $1.464B (+9% YoY); GAAP EPS $2.64 (+2%); non-GAAP EPS $2.95 (+16%).","FY2026 revenue $5.653B (+10%); GAAP EPS $10.43; non-GAAP EPS $11.17 (+17%).","FY2026 free cash flow $1.6B; returned $1.0B to shareholders; FY2027 capital return guided >$1.85B.","Dividend increased 10% to $0.66/quarter; record date Aug 20, payable Sep 24.","Agreement to sell MatrixCare (close Q1 FY2027); completed acquisition of Noctrix Health."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1501396,"accession_number":"0001193125-26-297658","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2026-07-07T21:24:32+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ResMed sells MatrixCare to Frazier Healthcare for $490M cash; sharpens focus on sleep health","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["All-cash deal valued at $490M, subject to closing adjustments; expected to close in Q1 FY2027.","MatrixCare had ~$220M revenue and ~$55M non-GAAP operating profit in FY2026.","Net proceeds to be used for share repurchases (ASR) and general corporate purposes.","Noctrix acquisition expected to add ~$30M revenue but reduce non-GAAP diluted EPS by ~$0.20 in FY2027.","ResMed reiterates FY2026 non-GAAP margin, SG&A, R&D, and tax rate outlook; full FY2027 guidance on Aug 6 call."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99934,"accession_number":"0001193125-26-197282","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ResMed CFO Brett Sandercock retires; Aaron Bloomer appointed successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brett Sandercock retires as CFO effective May 4, 2026; remains special advisor to CEO through Dec 2027.","Aaron Bloomer appointed CFO effective May 4; previously CFO of Exact Sciences (recently acquired by Abbott).","Bloomer compensation: $725k salary, $150k sign-on bonus, $3.3M equity grant (RSUs/PSUs with TSR metrics).","Resmed reiterates FY2026 guidance: gross margin 62-63%, SG&A 19-20%, R&D 6-7%, tax rate 21-23%.","Sandercock's retirement not due to any disagreement; retains salary, benefits and equity vesting through 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99933,"accession_number":"0001193125-26-197192","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"ResMed Q3 revenue $1.43B (+11%); GAAP EPS $2.74, dividend $0.60","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1,431.4M (+11% reported, +8% constant currency).","GAAP diluted EPS $2.74 (+10% YoY); non-GAAP diluted EPS $2.86 (+21% YoY).","GAAP gross margin 62.2% (+290 bps); non-GAAP gross margin 62.8% (+290 bps).","Quarterly dividend $0.60/share declared; record 5/14/2026, payable 6/18/2026.","Operating cash flow $554M; $262M returned via buybacks and dividends in Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":7.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":4189796000.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116233,"accession_number":"0001193125-26-029326","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"ResMed Q2 FY2026: Revenue $1.42B (+11% YoY), non-GAAP EPS $2.81, dividend $0.60","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1,422.8M, up 11% YoY (9% constant currency); gross margin expanded 320 bps to 61.8%.","GAAP diluted EPS $2.68; non-GAAP diluted EPS $2.81, up 16% YoY.","Operating cash flow $340M; income from operations rose 18% YoY.","Board declared quarterly cash dividend of $0.60/share, record Feb 12, payable Mar 19."],"consensus_eps_estimate":null,"consensus_eps_actual":5.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":2758390000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132694,"accession_number":"0001193125-25-289878","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Director Sulpizio not re-elected; board shrinks to 11; stockholders approve equity plan amendments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Richard Sulpizio did not seek re-election at Nov 19 annual meeting; board reduced from 12 to 11 directors.","Stockholders approved 2009 Incentive Award Plan amendment, adding 2.4M shares and eliminating fixed term.","Stockholders approved ESPP amendment, adding 3.0M shares and eliminating fixed term.","All 11 director nominees elected; KPMG ratified as auditor; say-on-pay approved (98.4M for, 11.0M against).","Plan amendments effective upon stockholder approval; detailed terms incorporated by reference to proxy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132693,"accession_number":"0001193125-25-258519","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"ResMed Q1 FY2026 revenue +9% to $1.34B; non-GAAP EPS $2.55 (+16%); dividend $0.60","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1,335.6M (+9% YoY, +8% constant currency); diluted EPS $2.37, non-GAAP EPS $2.55 (+16%).","Gross margin up 290 bps to 61.5%; non-GAAP gross margin 62.0% (up 280 bps).","Operating cash flow $457M; income from operations +15% (+19% non-GAAP).","Board declared quarterly dividend of $0.60 per share, payable Dec 18 to holders of record Nov 13."],"consensus_eps_estimate":null,"consensus_eps_actual":2.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":1335582000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149213,"accession_number":"0001193125-25-182695","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ResMed elects AbbVie's Nicole Mowad-Nassar to board; director Sulpizio to retire in Nov 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nicole Mowad-Nassar elected to ResMed board effective Aug 15, 2025; she is SVP at AbbVie and President of Specialty & U.S. Therapeutics Operations.","She will serve on the Compensation and Leadership Development Committee; term expires at 2025 annual meeting on Nov 19, 2025.","Director Richard Sulpizio to retire after 20 years, not standing for reelection at Nov 19 meeting; no disagreement with company.","Sulpizio previously chaired Compensation, Audit, and Nominating & Governance committees during his tenure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149212,"accession_number":"0001193125-25-170718","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ResMed CCO of residential care software business resigns effective Aug 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bobby Ghoshal, chief commercial officer of ResMed's RCS business, resigns effective August 1, 2025.","He is departing to become COO of a software company in a non-competitive industry.","No replacement has been announced; resignation is voluntary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149211,"accession_number":"0001193125-25-170512","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"ResMed Q4 revenue up 10% to $1.35B, EPS $2.58; dividend raised 13% to $0.60","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $1.35B (+10% YoY, +9% CC); GAAP EPS $2.58 (+30%), non-GAAP EPS $2.55 (+23%).","Gross margin up 230bps to 60.8% GAAP; operating income $454.5M (+19%).","FY2025 revenue $5.15B (+10%); GAAP EPS $9.51 (+37%).","Dividend raised 13% to $0.60/share; payable Sept 18, record Aug 14; ex-div Aug 13."],"consensus_eps_estimate":null,"consensus_eps_actual":9.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":5146327000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168231,"accession_number":"0001193125-25-091357","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"ResMed Q3 FY2025: revenue $1.29B (+8%), GAAP EPS $2.48 (+22%), non-GAAP EPS $2.37 (+11%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $1.29B (+8% YoY; +9% constant currency); GAAP diluted EPS $2.48 vs $2.04 (+22%).","Gross margin improved 140 bps to 59.3%; non-GAAP gross margin 59.9%.","Operating income up 14% to $426.3M; non-GAAP operating income up 13% to $444.6M.","Operating cash flow of $579M in the quarter.","Quarterly dividend of $0.53/share declared; payable June 12, 2025 to holders of record May 8, 2025."],"consensus_eps_estimate":2.5799,"consensus_eps_actual":6.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":3798334000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185422,"accession_number":"0001193125-25-017218","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"ResMed reports Q2 FY2025 revenue up 10% to $1.28B; non-GAAP EPS $2.43, up 29%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.28B (+10% YoY); gross margin 58.6% (+300 bps) on manufacturing efficiencies.","Non-GAAP diluted EPS $2.43 (+29%); operating income $417M (+52% vs $275M, prior year had $64M restructuring).","Operating cash flow $309M; paid $78M dividends and repurchased $75M shares during quarter.","Board declared $0.53 quarterly dividend; record Feb 13, 2025, payable Mar 20, 2025.","Residential Care Software revenue up 8% constant currency; U.S./Canada/Latin America revenue up 12%."],"consensus_eps_estimate":null,"consensus_eps_actual":4.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":2506598000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202007,"accession_number":"0001193125-24-263501","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"ResMed stockholders elect all 11 director nominees, ratify KPMG, approve say-on-pay at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 11 director nominees elected with strong support; vote tallies ranged from ~88M to ~109M in favor.","KPMG LLP ratified as independent auditor for fiscal 2025 with 105,082,628 for, 10,096,722 against.","Advisory say-on-pay resolution approved with 92,885,004 for, 17,284,647 against.","No material changes to board composition or executive compensation structure disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202006,"accession_number":"0001193125-24-242806","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"ResMed Q1 FY2025 revenue $1.22B (+11% YoY); EPS $2.11; non-GAAP EPS $2.20; dividend $0.53","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1,224.5M, up 11% YoY (11% constant currency), driven by sleep device and mask demand.","GAAP diluted EPS $2.11; non-GAAP diluted EPS $2.20, up 34% YoY; operating profit up 34%.","Gross margin improved to 58.6% (non-GAAP 59.2%), up 420 bps YoY on manufacturing efficiencies.","Operating cash flow $326M; paid $78M dividends and repurchased $50M shares.","Board declared quarterly dividend of $0.53 per share, record date Nov 7, payable Dec 12."],"consensus_eps_estimate":null,"consensus_eps_actual":2.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":1224509000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218049,"accession_number":"0001193125-24-202204","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ResMed appoints Christopher DelOrefice to board of directors, effective August 15, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["DelOrefice is EVP and CFO of Becton Dickinson, brings 30+ years of audit, finance and strategic expertise.","Board expanded to 11 members; DelOrefice will serve on audit committee.","Appointment effective immediately; will stand for re-election at Nov 21, 2024 annual meeting.","DelOrefice previously served as VP Investor Relations at Johnson & Johnson and CFO of North America Hospital Medical Devices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218048,"accession_number":"0001193125-24-191487","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"ResMed Q4 revenue $1.22B (+9% YoY); EPS $1.98; dividend up 10% to $0.53","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 FY2024 revenue $1,223.2M (+9% YoY, +10% constant currency); gross margin 58.5% (+350 bps).","GAAP diluted EPS $1.98 (+27% YoY); non-GAAP diluted EPS $2.08 (+30% YoY).","Operating cash flow $440M; debt repayments of $300M in Q4; FY2024 operating cash flow $1.4B.","Quarterly dividend increased 10% to $0.53 per share (payable Sept 19, record Aug 15).","Investor Day announced for September 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":6.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":4685297000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237998,"accession_number":"0001193125-24-113883","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"ResMed Q3 FY2024 revenue $1.20B, +7% YoY; GAAP EPS $2.04, non-GAAP $2.13","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.197B up 7% YoY (7% constant currency); mask/accessories double-digit growth.","Gross margin expanded 260 bps to 57.9%; non-GAAP 58.5%.","Operating profit $374.6M (+25%); non-GAAP operating profit $393.6M (+23%).","Diluted GAAP EPS $2.04 (+29%); non-GAAP EPS $2.13 (+27%).","Quarterly dividend $0.48, record May 9, payable June 13."],"consensus_eps_estimate":null,"consensus_eps_actual":4.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":3462102000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255475,"accession_number":"0001193125-24-014223","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2024-01-24T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"ResMed Q2 FY2024 revenue $1.16B (+12% YoY); non-GAAP EPS $1.88 (+13%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1,162.8M (+12% YoY, +11% constant currency); GAAP op profit down 2%, non-GAAP op profit up 20% to $365.5M.","GAAP diluted EPS $1.42 (-7%); non-GAAP diluted EPS $1.88 (+13%), driven by revenue growth and cost discipline.","Board declared $0.48/share quarterly cash dividend with record date Feb 8, payable March 14.","Resumed share repurchase program; repurchased $50M of common stock during the quarter.","Gross margin contracted 50 bps to 55.6% GAAP; non-GAAP gross margin improved 10 bps to 56.9%."],"consensus_eps_estimate":null,"consensus_eps_actual":2.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":2265122000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272932,"accession_number":"0001193125-23-280656","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2023-11-20T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"ResMed amends bylaws for universal proxy rules; annual meeting results filed","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board adopted amended bylaws on Nov 17, 2023, addressing SEC universal proxy rules (Rule 14a-19) and restricting proxy card color.","Stockholders elected all 10 director nominees; votes ranged from 91.5M (Sulpizio) to 102.5M (De Witte).","KPMG ratified as auditor for FY ending June 30, 2024: 105.1M for, 6.0M against.","Say-on-pay approved on advisory basis: 84.3M for, 19.6M against; future say-on-pay votes set to annual.","Bylaw amendments include technical, ministerial, and DGCL-alignment updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272931,"accession_number":"0001193125-23-274543","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ResMed appoints new CPO, CMO, CRO; COO Douglas to retire Jan 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rob Douglas, President & COO, retires Jan 1, 2024; transitions to special advisor to CEO immediately.","Justin Leong named Chief Product Officer, Katrin Pucknat as CMO, Mike Fliss as CRO, effective immediately.","Lucile Blaise moves from president sleep & respiratory care to SVP strategy & business development.","New operating model sets product-led, customer-centric, brand-enhanced focus to accelerate profitable growth.","Former CTO Urvashi Tyagi becomes special advisor to CPO through Jan 1, 2024; consulting through Dec 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272930,"accession_number":"0001193125-23-264072","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2023-10-26T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"ResMed Q1 FY2024 revenue up 16% to $1.10B; non-GAAP EPS $1.64 (+9% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1,102.3M (+16% YoY); operating income $289.0M (+5%); non-GAAP operating profit +10%.","Diluted EPS $1.49 (GAAP) and $1.64 (non-GAAP, +9% YoY); gross margin 54.4%, down 250 bps.","Operating cash flow $286.3M; company expects to resume share repurchase program in upcoming quarter.","Board declared quarterly dividend of $0.48/share, payable Dec 14, record Nov 9."],"consensus_eps_estimate":null,"consensus_eps_actual":1.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":1102321000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289774,"accession_number":"0001193125-23-202850","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"ResMed Q4 FY2023 revenue up 23% to $1.12B; EPS $1.56 GAAP, dividend raised 9% to $0.48","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1,122.1M +23% YoY; GAAP diluted EPS $1.56 (+17%), non-GAAP $1.60 (+7%).","Full-year revenue $4,223.0M (+18%); GAAP EPS $6.09 (+15%), non-GAAP $6.44 (+11%).","Gross margin contracted 210 bps to 55.0% (GAAP) and 200 bps to 55.8% (non-GAAP).","Quarterly dividend raised 9% to $0.48/share; record Aug 17, payable Sept 21, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":6.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":4222993000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310676,"accession_number":"0001193125-23-122110","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2023-04-27T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"ResMed Q3 FY2023 revenue +29% to $1.12B; EPS $1.58, non-GAAP $1.68","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1,116.9M, up 29% YoY (31% constant currency); diluted EPS $1.58, non-GAAP $1.68.","Operating income +28% to $300.7M; non-GAAP operating income +27% to $321.2M.","Gross margin contracted 150 bps to 55.3%; non-GAAP gross margin down 200 bps to 56.1%.","CEO: full global availability of AirSense 10; ramping AirSense 11; strong mask and SaaS growth.","Quarterly dividend $0.44/share declared; payable June 15, record May 11."],"consensus_eps_estimate":null,"consensus_eps_actual":4.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":3100936000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329309,"accession_number":"0001193125-23-085659","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2023-03-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ResMed Announces Retirement of Chief Administrative Officer and General Counsel David Pendarvis","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Pendarvis, global general counsel and chief administrative officer, will retire effective June 30, 2023, after over 20 years at ResMed.","Pendarvis will serve as a consultant from July 1 to December 31, 2023, at a rate of $10,000 per month.","Amy Wakeham has been appointed Chief Communications and Investor Relations Officer, effective April 1, 2023, and will join the executive leadership team.","ResMed will conduct an internal search for a successor global general counsel and secretary.","Pendarvis will remain eligible for a short-term incentive cash payment for fiscal year 2023 based on continued employment through June 30."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329308,"accession_number":"0001193125-23-016231","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2023-01-26T23:59:59+00:00","items":["2.02","5.02","8.01","9.01"],"status":"ready","headline":"ResMed Q2 revenue up 16% to $1.03B, EPS $1.53; CEO Farrell appointed Board Chair","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1,033.7M (+16% YoY, +20% constant currency); GAAP EPS $1.53, non-GAAP $1.66.","Gross margin contracted 30 bps to 56.1%; non-GAAP gross margin 56.8%.","Mick Farrell, current CEO, named Board Chair; founder Peter Farrell becomes Chair Emeritus.","Quarterly dividend $0.44/share declared, payable March 16, record date Feb 9.","Closed acquisition of MEDIFOX DAN in Germany, expanding out-of-hospital SaaS business."],"consensus_eps_estimate":null,"consensus_eps_actual":2.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":1984038000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346926,"accession_number":"0001193125-22-287662","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2022-11-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"ResMed shareholders elect all directors, approve say-on-pay; two directors see ~11% votes against","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 10 board nominees elected; most received >95% support with few against.","Ratification of KPMG as FY2023 auditor passed with 113.9M for, 6.0M against.","Advisory say-on-pay approved with 103.4M for (88%), 11.6M against (10%).","Directors Sulpizio and Taylor each had >12M votes against (~11% of votes cast), highest dissent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346925,"accession_number":"0001193125-22-270961","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2022-10-27T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"ResMed Q1 FY23 revenue $950.3M (+5% YoY, +9% CC); GAAP EPS $1.43, non-GAAP $1.51","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $950.3M, up 5% YoY (9% constant currency); Americas (ex-SaaS) revenue up 18%.","GAAP operating profit $275.7M (+5%), non-GAAP operating profit $290.8M (+4%).","GAAP diluted EPS $1.43 vs $1.39; non-GAAP diluted EPS $1.51 flat YoY.","Board declared quarterly dividend $0.44/share, payable Dec 15, 2022, record Nov 10.","Acquired mementor (German digital sleep medicine); opened new R&D facility in Ireland."],"consensus_eps_estimate":null,"consensus_eps_actual":1.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":950294000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363306,"accession_number":"0001193125-22-218896","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K/A","filed_at":"2022-08-12T23:59:59+00:00","items":["8.01","1.01","7.01","9.01"],"status":"ready","headline":"ResMed to acquire MediFox-Dan for EUR 810M; closing expected by Dec 31, 2022","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Base purchase price of EUR 810M fixed via locked box; enterprise value EUR 950M.","Funded with existing cash and borrowings under credit facility; intercompany loan to ResMed Germany SaaS.","Closing subject to German merger control, foreign investment, and BaFin clearances.","Termination fee of EUR 10M payable to seller if BaFin clearance not obtained.","Acquisition of 100% of MediFox-Dan shares and shareholder loan receivables."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363308,"accession_number":"0001193125-22-218522","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"ResMed Q4 revenue $914.7M (+4% YoY); dividend up 5% to $0.44; acquires MEDIFOX DAN for $1B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $914.7M (+4% YoY, +8% constant currency); GAAP diluted EPS $1.33.","Full-year revenue $3.58B (+12% YoY, +13% constant currency); GAAP EPS $5.30.","Quarterly dividend raised 5% to $0.44/share, payable Sept 22, record Aug 18.","Announced $1B acquisition of MEDIFOX DAN, a German out-of-hospital software company; expected close by Dec 31, 2022.","Lucile Blaise promoted to President of Sleep & Respiratory Care effective July 1, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":5.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":3578127000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363307,"accession_number":"0001193125-22-187014","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2022-07-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ResMed promotes Lucile Blaise to President of Sleep & Respiratory Care effective July 1","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lucile Blaise, previously VP of Sleep & Respiratory Care for Western Europe, promoted to President of global Sleep & Respiratory Care, effective July 1, 2022.","Blaise has over 25 years in medtech, including 16 years at ResMed; elected President of Snitem in June 2022 and serves on MedTech Europe board.","Compensation: annual base salary $470,000, target STI 80%, equity target $1,400,000, plus relocation benefits for move to U.S.","Robert Douglas will cease as interim President of the business but remains President and COO of ResMed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383078,"accession_number":"0001193125-22-186327","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2022-06-30T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"ResMed enters amended $1.5B revolver and $200M term loan, both maturing June 2027","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Revolver reduced from $1.6B to $1.5B; includes uncommitted $1B increase option.","New $200M term loan from ResMed Pty subsidiary; amortizes $5M semi-annually.","Both facilities mature June 29, 2027; interest at SOFR+0.75%-1.50% or Base Rate+0.0%-0.50%.","Proceeds for general corporate purposes; financial covenant maintains max leverage ratio.","Obligations guaranteed by specified U.S. subsidiaries including Brightree and MatrixCare."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383077,"accession_number":"0001193125-22-173521","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2022-06-14T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"ResMed to acquire German out-of-hospital software leader MEDIFOX DAN for ~$1B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price ~US$1.0B (€950M); expected to close by Dec 31, 2022 subject to German regulatory clearances.","MEDIFOX DAN CY2021 pro forma revenue ~$83M, adjusted EBITDA ~$35M; deal expected accretive to non-GAAP EPS.","Expands ResMed's SaaS business into Germany; MEDIFOX DAN brand and management to continue under ResMed SaaS.","Co-managing directors Dr. Thorsten Schliebe and Christian Städtler will remain, reporting to ResMed SaaS President.","ResMed to fund via existing credit facilities; Evercore and DLA Piper serving as advisors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383076,"accession_number":"0001193125-22-147554","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2022-05-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ResMed President of Sleep and Respiratory Care Jim Hollingshead resigns; Rob Douglas named interim","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jim Hollingshead resigned effective May 5, 2022 to pursue a new opportunity.","Rob Douglas, ResMed's President and COO, appointed interim president of Sleep and Respiratory Care.","CEO Mick Farrell acknowledged Hollingshead's 12 years of service and contributions.","Company will begin a search for a permanent president for the sleep and respiratory care business."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383075,"accession_number":"0001193125-22-127535","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2022-04-28T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"ResMed Q3 revenue up 12% to $864.5M; non-GAAP EPS $1.32, up 2% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $864.5M (+12% YoY); constant currency growth 14%.","GAAP diluted EPS $1.22 (up from loss of $0.54); non-GAAP diluted EPS $1.32 (+2%).","Gross margin contracted 140 bps to 56.8%; non-GAAP gross margin contracted 150 bps to 58.1%.","Board declared $0.42/share dividend, record May 12, payable June 16, 2022.","CEO cites strong sleep/respiratory demand but supply chain disruptions limit ability to meet demand."],"consensus_eps_estimate":null,"consensus_eps_actual":3.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":2663390000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400899,"accession_number":"0001193125-22-019765","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2022-01-27T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"ResMed Q2 FY2022: Revenue $894.9M (+12% YoY), GAAP EPS $1.37, non-GAAP $1.47; dividend $0.42","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $894.9M, up 12% YoY (13% constant currency); operating income $248.7M, up 12%.","GAAP diluted EPS $1.37 (up 11%); non-GAAP diluted EPS $1.47 (up 4%).","Gross margin contracted 140 bps GAAP to 56.4%; non-GAAP gross margin down 230 bps to 57.6%.","Board declared quarterly cash dividend $0.42/share, payable March 17, 2022, record date Feb 10.","CEO cited strong demand from competitor device recall, ongoing supply chain constraints."],"consensus_eps_estimate":null,"consensus_eps_actual":2.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":1798890000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":419854,"accession_number":"0001193125-21-334941","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2021-11-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"ResMed shareholders elect all seven director nominees, ratify auditor, approve say-on-pay at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven board nominees elected; highest vote for Harjit Gill (111.4M for), lowest for Ronald Taylor (104.1M for).","KPMG LLP ratified as independent auditor for FY 2022 with 112.7M votes for, 4.2M against.","Advisory say-on-pay resolution passed with 99.2M for, 12.2M against, 5.4M broker non-votes.","Annual meeting held November 18, 2021; all items approved by stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":419853,"accession_number":"0001193125-21-311286","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2021-10-28T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"ResMed reports Q1 FY2022 revenue $904M (+20% YoY), diluted EPS $1.39, non-GAAP EPS $1.51","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $904.0M, up 20% YoY (19% constant currency); all segments grew double-digits.","Diluted EPS $1.39 (+14% YoY); non-GAAP diluted EPS $1.51 (+19% YoY).","Income from operations $261.9M (+21%); non-GAAP operating profit $280.7M (+18%).","Board declared quarterly cash dividend of $0.42/share, payable Dec 16, 2021, record Nov 11.","CEO cited strong demand but ongoing supply chain constraints limiting electronic components."],"consensus_eps_estimate":null,"consensus_eps_actual":1.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":904015000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":419852,"accession_number":"0001193125-21-294033","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K/A","filed_at":"2021-10-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ResMed provides separation terms for former SaaS president: $704K severance, consulting deal","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rajwant Sodhi resigned as president of SaaS business effective Aug 25, 2021; termination without cause.","Separation payments: $603,500 base, $80,647 pro-rata incentive, $19,544 COBRA; total ~$703,691.","Consulting agreement from Sept 2, 2021 to Nov 20, 2022; continued vesting of equity awards during term.","Sodhi agreed to non-disclosure, non-compete, and general release of ResMed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":437411,"accession_number":"0001193125-21-271405","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2021-09-13T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"ResMed amends bylaws to reduce special meeting threshold from majority to 20%","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved seventh amended and restated bylaws effective September 10, 2021.","Special meetings now callable by holders of at least 20% of outstanding shares (previously majority).","Amendment lowers the barrier for shareholders to call special meetings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":437410,"accession_number":"0001193125-21-259336","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2021-08-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ResMed promotes Bobby Ghoshal to president of SaaS business; Raj Sodhi departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rajwant Sodhi will cease as president – SaaS business on Aug 25, full-time employment ends Sept 1.","Termination is without cause; company is in discussions regarding a separation package.","Bobby Ghoshal, age 53, promoted to president – SaaS business effective Aug 25, 2021.","Ghoshal served as CTO since April 2018; previously COO at Brightree and VP of IT at ResMed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":437409,"accession_number":"0001193125-21-237704","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2021-08-05T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"ResMed Q4 FY2021 revenue up 14% to $876.1M, dividend increased 8% to $0.42","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $876.1M (+14% YoY); non-GAAP operating profit up 7%; diluted non-GAAP EPS $1.35.","Full-year FY2021 revenue $3.2B (+8% YoY); non-GAAP operating profit up 12%; non-GAAP EPS $5.33 (+12%).","Quarterly dividend raised 8% to $0.42/share; payable Sep 23, record Aug 19.","Company cites ongoing recovery in sleep apnea patient flow and tailwind from competitor quality issue.","GAAP net income down 24% for FY due to prior-year gain; non-GAAP net income up 13%."],"consensus_eps_estimate":null,"consensus_eps_actual":3.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":3196825000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}